Injectable Peptides – The New Snake Oil

The U.S. is experiencing a surge in unregulated injectable peptides, a trend critics liken to historical 'snake oil' scams. While the FDA historically restricted unproven health products, loopholes—such as the 1994 Dietary Supplement Health and Education Act (DSHEA)—created gaps allowing dubious claims under 'structure-function' rules. These loopholes fueled a multi-billion-dollar 'wellness' industry promoting anti-vaccine conspiracy theories and science denial, now reaching its peak with movements like MAHA influencing federal policy. Injectable peptides, chains of amino acids, are not inherently dangerous, as FDA-approved drugs like insulin and GLP-1 medications prove. However, many peptides sold today bypass FDA approval by being classified as biologics, regulated through compounding pharmacies. These pharmacies operate under three categories: Category 1 (FDA-reviewed), Category 2 (too risky), and Category 3 (insufficient evidence). Peptides often fall into Category 3, allowing their sale without rigorous testing, despite their potential risks. The article argues that compounding pharmacies exploit regulatory ambiguity, selling peptides with unproven benefits while avoiding FDA scrutiny. This mirrors past supplement industry abuses, where vague 'structure-function' claims bypassed drug regulations. The current peptide craze, amplified by social media and anti-regulation sentiment, risks repeating the exploitation of public trust seen with past wellness trends. Critics warn that without stronger oversight, injectable peptides could become another chapter in the U.S.'s history of unproven health products. The rise of movements like MAHA—aligned with federal anti-regulation efforts—further threatens consumer protection. The piece emphasizes the need for stricter FDA enforcement to prevent another era of unchecked medical fraud.